Palbociclib plus endocrine therapy in hormone receptor ...
Palbociclib plus ET showed a median PFS of 12.2 months in HR+/HER2- MBC patients, with a DCR of 90.5%. Earlier Palbociclib initiation is supported, showing benefits across treatment lines. Differences in outcomes may stem from patient demographics and prior treatments. Real-world data from China adds valuable insights, despite limitations.
Reference News
Palbociclib plus endocrine therapy in hormone receptor ...
Palbociclib plus ET showed a median PFS of 12.2 months in HR+/HER2- MBC patients, with a DCR of 90.5%. Earlier Palbociclib initiation is supported, showing benefits across treatment lines. Differences in outcomes may stem from patient demographics and prior treatments. Real-world data from China adds valuable insights, despite limitations.